IPNews® – The Federal Circuit on Friday affirmed a Texas federal court’s patent infringement finding and accompanying injunction barring three generic drug manufacturers from making, selling or marketing generic versions of Pozen Inc.’s migraine treatment Treximet.

Par Pharmaceutical Inc., Alphapharm Pty Ltd. and Dr. Reddy’s Laboratories Inc. could not overcome the presumption of validity of issued patents, and provided no reason to unsettle the Texas court’s infringement finding, the Federal Circuit ruled. The Texas court rightly upheld the validity of Pozen’s three patents in the face of the generics companies’ claims that the patents were obvious, the appeals court said. To continue reading, click: Pozen Migraine Drug Patent Win Upheld By Federal Circuit